Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1). (October 2019)

• Record Type: Journal Article
• Authors: Loebinger, Michael R.; Polverino, Eva; Blasi, Francesco; Elborn, Stuart J.; Chalmers, James D.; Tiddens, Harm AWM.; Goossens, Herman; Tunney, Michael; Zhou, Wenchun; Angyalosi, Gerhild; Hill, Adam T.; Haworth, Charles S.
• Is Part Of: Pulmonary pharmacology & therapeutics. Volume 58(2019)
• Publication Date: 2019-10
• Subjects: Tobramycin inhalation powder -- Bronchiectasis -- Sputum Pa density -- Dose and regimen; Respiratory organs -- Diseases -- Chemotherapy -- Periodicals; 615.7205
• DOI: 10.1016/j.pupt.2019.101834
• Languages: English
• ISSNs: 1094-5539

Abstract

Abstract: In patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa ( Pa ) results in disease progression, frequent pulmonary exacerbations and lung function decline. However, at present, no inhaled antibiotics have been approved for the treatment of these patients. Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate. We aimed to assess effective and well-tolerated doses and regimens of TIP in BE patients with Pa infection. In this phase II, double-blind, placebo-controlled, randomised study, three different daily doses of TIP are administered either as continuous or cyclical regimens. The study protocol comprises 7–28 days of screening, 112 days of double-blind treatment and 56 days of follow-up. The plan was to enrol 180 patients (aged ≥18 years) with BE, documented Pa infection and a history of exacerbations. The primary outcome is change in sputum Pa density from baseline. Key secondary outcomes include number of pulmonary exacerbations, use of antipseudomonal antibiotics, serum and sputum tobramycin concentrations, quality of life and safety. Exploratory endpoints include lung clearance index, sputum inflammatory markers and microbiome analysis. As of October 2018, 107/180 patients were enrolled at 34 sites (six countries) following which recruitment was closed for administrative reasons unrelated to safety findings. Despite a reduced sample size from initially planned enrolment, the unique design may inform the benefit-risk profile of TIP in BE patients with chronic Pa infection. Moreover, several novel and exploratory endpoints (lung clearance index, inflammatory biomarkers, lung microbiome), will contribute to the advancement of research in this area.